Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Dermatology IND Enabling
South Korea 
Details:
BRE-AD01 is produced from stem cells (named 'BxC') stimulated with a specified, well-defined clinical available compound, which comprised the backbone of Brexogen's technology.
Lead Product(s): BRE-AD01
Therapeutic Area: Dermatology Product Name: BRE-AD01
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
LEM-S401 is a siRNA gene therapy drug that can treat and prevent hypertrophic scars, also claims to minimize the incidence of scars and the ability to remove pre-existing scars, increasing quality of life for patients.
Lead Product(s): LEM-S401
Therapeutic Area: Dermatology Product Name: LEM-S401
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
VB517 is a fully human mAb with low-picomolar affinity for c-KIT and has demonstrated potent suppression of human mast cell activation in preclinical models. ValenzaBio plans to initiate clinical studies of VB517 in 2023.
Lead Product(s): VB517
Therapeutic Area: Dermatology Product Name: VB517
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: ValenzaBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 15, 2022
